Adrenomedullin in Cancer: Tumor Growth Promoter, Angiogenesis Driver, and Potential Drug Target
Adrenomedullin is overexpressed by many tumors where it promotes growth, drives angiogenesis (tumor blood supply), and suppresses anti-tumor immunity — making it a potential cancer drug target.
Quick Facts
What This Study Found
Adrenomedullin is overexpressed in many cancers where it promotes tumor growth, drives angiogenesis (tumor blood vessel formation), and may suppress anti-tumor immunity — positioning it as a multi-mechanism cancer therapy target.
Key Numbers
How They Did This
Review of adrenomedullin expression in human cancers, its effects on tumor cell proliferation, angiogenesis, and immune modulation, with therapeutic targeting implications.
Why This Research Matters
Tumors need blood supply and immune evasion to grow. AM provides both. Blocking it could attack cancer from two directions simultaneously — an efficient therapeutic strategy.
The Bigger Picture
Cancer exploits normal body systems for its benefit. AM's hijacking by tumors for blood supply and immune evasion exemplifies how cancer subverts physiology — and how blocking subverted systems can fight cancer.
What This Study Doesn't Tell Us
Review of early-stage cancer AM biology. The therapeutic potential of AM blockade in cancer was largely conceptual at the time.
Questions This Raises
- ?Could AM-blocking antibodies or receptor antagonists treat cancer?
- ?Which cancer types are most dependent on AM?
- ?Would AM blockade affect normal vascular function?
Trust & Context
- Key Stat:
- Triple cancer support Adrenomedullin helps tumors grow + build blood vessels + suppress immunity — blocking it attacks cancer from three directions
- Evidence Grade:
- Moderate evidence from a review synthesizing AM expression, functional, and mechanistic data across multiple cancer types.
- Study Age:
- Published in 2003. AM's role in cancer has been further confirmed, and AM-related biomarkers and therapies are being developed.
- Original Title:
- Adrenomedullin and cancer.
- Published In:
- Regulatory peptides, 112(1-3), 175-83 (2003)
- Authors:
- Zudaire, E, Martínez, A, Cuttitta, F(2)
- Database ID:
- RPEP-00876
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
How does adrenomedullin help cancer?
Tumors overexpress AM to: (1) grow faster, (2) build their own blood supply (angiogenesis), and (3) suppress the immune system's ability to attack them. It's a triple survival strategy that tumors exploit.
Could blocking adrenomedullin treat cancer?
Potentially. AM-blocking drugs could simultaneously cut off tumor blood supply and restore anti-tumor immunity — attacking cancer from multiple directions with one target.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00876APA
Zudaire, E; Martínez, A; Cuttitta, F. (2003). Adrenomedullin and cancer.. Regulatory peptides, 112(1-3), 175-83.
MLA
Zudaire, E, et al. "Adrenomedullin and cancer.." Regulatory peptides, 2003.
RethinkPeptides
RethinkPeptides Research Database. "Adrenomedullin and cancer." RPEP-00876. Retrieved from https://rethinkpeptides.com/research/zudaire-2003-adrenomedullin-and-cancer
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.